At a glance
ClinicalIndex Comparison RecordN/ACompleted· 392 enrolled
Drug / intervention
Fixed combination 0.3 mg bimatoprost and 5 mg timololdrug
Likely dose
Fixed combination 0.3 mg bimatoprost and 5 mg timololfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
GANfort® in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Who Are Insufficiently Responsive to Monotherapy
In Brief
An observational study evaluating Fixed combination 0.3 mg bimatoprost and 5 mg timolol for Glaucoma, Open-Angle and Ocular Hypertension. Completed, enrolled 392 participants across 1 site.
Detailed Summary
This is an observational study of patients diagnosed with Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) who are insufficiently responsive to monotherapy and who are prescribed GANfort® (fixed combination of 0.3 mg bimatoprost and 5 mg timolol) by their physician.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Open-Angle, Ocular Hypertension
CountriesAustria
Collaborators--
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2010
Primary CompletionJun 2011
First PostedJun 2012
TodayJul 2026
First PostedJun 27, 2012
Enrollment StartMay 1, 2010
Primary CompletionJun 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 14.0 years ago
Interventions
Fixed combination 0.3 mg bimatoprost and 5 mg timololdrug
Patients with POAG or OHT prescribed GANfort® (fixed combination 0.3 mg bimatoprost and 5 mg timolol) treatment in a dose determined by the physician prior to study entry